Explore the advantages of continuous glucose monitors and their reliance on precise electronic components for accurate data ...

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to ...

Cheng Xin / Getty Images Shares of DexCom (DXCM) jumped more than 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices for people with diabetes reported ...

Shares of DexCom (DXCM) jumped more than 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices for people with diabetes reported better-than-expected ...

Devices like Dexcom’s Stelo and Abbott’s Lingo are no longer just for people managing diabetes with a prescription – they’re now available to anyone who wants insight into how blood sugar ...

It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. On May 5, Analyst Mike Kratky from Leerink ...

Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered ...

Dexcom reaffirmed its 2025 revenue guidance of $4.6 billion, representing 14% growth. The company also maintained its operating margin and adjusted EBITDA margin guidance at approximately 21% and ...

In this article, we are going to take a look at where DexCom Inc. (NASDAQ:DXCM) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...